|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pharmacological Therapeutics:Current Trends for Metabolic Dysfunction-associated Fatty Liver Disease(MAFLD)显示文摘Metabolic dysfunction-associated fatty liver disease(MAFLD)is a new term from nonalcoholic fatty liver disease(NAFLD)and is a positive diagnosis based on histopathology,imaging,or blood biomarkers.MAFLD is one of the common causes of liver dysfunction worldwide,likely due to the increase in metabolic syndrome as well as the high burden of disease and its relationship to other extrahepatic conditions.However,effective pharmacological therapeutic agents are still lacking;current management largely focuses on weight reduction and lifestyle modification.The purpose of this review was to summarize the updated evidence of novel therapies targeting different pathogenetic pathways in MAFLD. | Thaninee Prasoppokakorn Panyavee Pitisuttithum Sombat Treeprasertsuk | 2021 | Journal of Clinical and Translational Hepatology2021，9，6： | 3 |
| 2 | Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand显示文摘 | Rerks-Ngarm S Pitisuttithum P Nitayaphan S | 2009 | N Engl J Med2009，361，23： | 1 |
| 3 | Randomized, double-blind, placebo-controlled efficacy trial of a bivalent re- combinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand 显示文摘 | Pitisuttithum P Gilbert P Gurwith M | 2006 | J Infect Dis2006，194，12： | 1 |
| 4 | Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial 显示文摘 | Mu oz N Manalastas R Jr Pitisuttithum P | 2009 | Lancet2009，373，9679： | 1 |
| 5 | Safety,immunogenicity,and efficacy of quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine in women aged 24-45 years:a randomised,double-blind trial显示文摘 | Mu(n)oz N Manalastas R Jr Pitisuttithum P | | 0，，9679： | 1 |
| 6 | PhaseⅠ/Ⅱ study of a candidate vaccine designed against the B and E subtypes of HIV- 1 显示文摘 | Pitisuttithum P Berman PW Phonrat B | 2004 | J Acquit Immune Defic Syndr2004，37，1： | 1 |
| 7 | Randomized, doubleblind, placebo controlled efficacy trial of a bivalent recombinant glyco-protein 120 HIV-1 vaccine among injection drug users in Bangkok,Thailand 显示文摘 | Pitisuttithum P Gilbert P Gurwith M | 2006 | J Infect Dis2006，194，12： | 1 |
| 8 | Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease:The Gut and Obesity Asia initiative显示文摘BACKGROUND Gamma-glutamyl transferase(GGT)is associated with the risk of cardiovascular disease(CVD)in the general population.AIM To identify the association of baseline GGT level and QRISK2 score among patients with biopsy-proven nonalcoholic fatty liver disease(NAFLD).METHODS This was a retrospective study involving 1535 biopsy-proven NAFLD patients from 10 Asian centers in 8 countries using data collected by the Gut and Obesity in Asia(referred to as“GO ASIA”)workgroup.All patients with available baseline GGT levels and all 16 variables for the QRISK2 calculation(QRISK2-2017;developed by researchers at the United Kingdom National Health Service;http://gffzz3d3435dbdf8b436dswn0qkobp5owu6uqf.ffgz.tsg.suse.edu.cn/2017/;10-year cardiovascular risk estimation)were included and compared to healthy controls with the same age,sex,and ethnicity.Relative risk was reported.QRISK2 score>10%was defined as the high-CVD-risk group.Fibrosis stages 3 and 4(F3 and F4)were considered advanced fibrosis.RESULTS A total of 1122 patients(73%)had complete data and were included in the final analysis;314(28%)had advanced fibrosis.The median age(interquartile range[IQR])of the study population was 53(44-60)years,532(47.4%)were females,and 492(43.9%)were of Chinese ethnicity.The median 10-year CVD risk(IQR)was 5.9%(2.6-10.9),and the median relative risk of CVD over 10 years(IQR)was 1.65(1.13-2.2)compared to healthy individuals with the same age,sex,and ethnicity.The high-CVD-risk group was significantly older than the low-risk group(median[IQR]:63[59-67]vs 49[41-55]years;P<0.001).Higher fibrosis stages in biopsy-proven NAFLD patients brought a significantly higher CVD risk(P<0.001).Median GGT level was not different between the two groups(GGT[U/L]:Median[IQR],high risk 60[37-113]vs low risk 66[38-103],P=0.56).There was no correlation between baseline GGT level and 10-year CVD risk based on the QRISK2 score(r=0.02).CONCLUSION The CVD risk of NAFLD patients is higher than that of healthy individuals.Baseline GGT level cannot predict CVD risk in NAFLD patients.However,advanced fibrosis is a predictor of a high CVD risk. | Panyavee Pitisuttithum Wah-Kheong Chan George Boon-Bee Goh Jian-Gao Fan Myeong Jun Song Phunchai Charatcharoenwitthaya Ajay Duseja Yock-Young Dan Kento Imajo Atsushi Nakajima Khek-Yu Ho Khean-Lee Goh Vincent Wai-Sun Wong Sombat Treeprasertsuk | 2020 | World Journal of Gastroenterology2020，26，19： | 1 |
| 9 | Activity of posaconazole in the treatment of central nervous system fungal infections显示文摘 | Pitisuttithum P Negroni R Graybill JR | 2005 | J Antimicrob Chemother2005，56，4： | 1 |
| 10 | A Prospective Study of AIDS-associated Cryptococcal Meningitis in Thailand Treated with High-dose Amphotericin B显示文摘 | PITISUTTITHUM p TANSUPHASAWADIKUL S SIMPSON AJ | 2001 | J Infect(S0022-1899)2001，43，4： | 1 |
| 11 | AIDS vaccine for Asia Network (AVAN):expanding the regional role in developing HIV vaccines显示文摘 | Kent SJ Cooper DA Chhi Vun M Shao Y Zhang L Ganguly N Bela B Tamashiro H Ditangco R Rerks-Ngarm S Pitisuttithum P Van Kinh N Bernstein A Osmanov S AIDS Vaccine for Asia Network Investigators and Supporters | 2010 | PLoS Med2010，7，10： | 1 |
| 12 | Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand 显示文摘 | Rerks-Ngarm S Pitisuttithum P Nitayaphan S | 2009 | N Engl J Med2009，361，23： | 1 |
| 13 | Mycobacterium tuberculosis infection among HIV/AIDS patients in Thailand :clinical manifestations and outcomes 显示文摘 | Putong N M Pitisuttithum P Supanaranond W | 2002 | Southeast Asian J Trop Med Public Health2002，33，2： | 1 |
| 14 | Vaccination with ALVAC and AIDSVAX to prevent HIV-I infection in Thailand 显示文摘 | Rerks-Ngarm S Pitisuttithum P Nitayaphan S | 2009 | N Engl J Med2009，361，23： | 1 |
| 15 | Safety, immunogenicity, and efficacy of quadrivalent human papillomavims ( types 6, 11, 16, 18) recombinant vaccine in women aged 24- 45 years: a randomised, double-blind trial显示文摘 | Munoz N Manalastas R Pitisuttithum P | 2009 | Lancet2009，373，： | 1 |
| 16 | Randomized,double-blind,placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok,Thailand显示文摘 | Pitisuttithum P Gilbert P Gurwith M Heyward W Martin M van Griensven F Hu D Tappero JW Choopanya K Bangkok Vaccine Evaluation Group | 2006 | J Infect Dis2006，194，12： | 1 |
| 17 | End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV ( types 6, 11, 16,18) recombinant vaceine in adult women 24-45 years of age 显示文摘 | Castellsague X Munoz N Pitisuttithum P et at | 2011 | Br J Cancer2011，105，1： | 1 |
| 18 | Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand 显示文摘 | Rerks-Ngarm S Pitisuttithum P Nitayaphan S Kaewkung- wal J Chiu J Paris R Premsri N Namwat C de Souza M Adams E Benenson M Gurunathan S Tartaglia J McNeil JG Francis DP Stablein D Birx DL Chunsuttiwat S Khamboonruang C Thongcharoen P Robb ML MichaelNL Kunasol P Kim JH MOPH-TAVEG Investigators | 2009 | N Engl J Med2009，361，23： | 1 |
| 19 | End-of-study safety,immunogenicity,and efficacy of quadrivalent HPV(types 6,11,16,18)recombinant vaccine in adult women 24-45 years of age显示文摘 | Castellsague X Munoz N Pitisuttithum P | 2011 | British journal of cancer2011，105，1： | 1 |
| 20 | Knowledge, attitudes, and acceptability of a human papillomavirus vaccine among healthcare providers显示文摘 | Songthap A Pitisuttithum P Kaewkungwal J | 2009 | Southeast Asian J Trop Med Public Health2009，40，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员